Many of these advances will offer vastly improved outcomes for patients, therapies for hitherto difficult-to-treat diseases or conditions, improved manufacturing efficiency, or better use of valuable medical professional resources. According to experts, some 130 new nanotechnology-based drugs and delivery systems were already under development in 2006.
The Institute of Nanotechnology, global leaders in nanotechnology information services, is organising its second annual nanomedicine conference and exhibition ‘Investing in Medical Nanotechnology II’, which will showcase the latest developments in nanomedicine and potential routes to financing. The two day event will see leading multinational companies such as Philips, AstraZeneca, GE Healthcare, GlaxoSmithKline, Volcano Corporation and Fresenius Medical Care sharing their vision on the impacts of nanomedicine on healthcare and providing a window on their activities in the area. The conference will also see top industry figures offering their views on how to manage ‘risks and uncertainties’ as well as the challenges in integrating nanomedicine into established pharmaceutical and medical device business models.
The Head of ‘Nanosciences and Nanotechnologies’ unit at The European Commission will outline the EC’s nanomedicine plan and how some of the €800million dedicated under FP7 will be targeted towards new nanotechnology-based treatments. The Wellcome Trust will present details about their funding priorities and new technology transfer initiatives, and the chairman of the US-based Aesis Research Group will discuss new business models, financing and valuation in medical nanotechnology and suggest ideas for building value.
The event will also see a number of innovative small companies present novel nanomedical technologies and presentations from top scientists from as far away as India and Malaysia. The associated exhibition will showcase new innovations in nanomedicine and will provide a unique opportunity to network with potential partners.
Investing in Medical Nanotechnology II builds upon the success of the inaugural event held last year to bring the latest developments in the exciting and dynamic new field of nanomedicine. The event is sponsored by Marks & Clerk, MTI Partners and Tinytech Jobs and will take place on 28-29 November at the historic and prestigious Royal College of Surgeons in London. Further details are available at http://nanomednet.org/conference07/ or alternatively contact Tiju Joseph at the Institute of Nanotechnology on +44 (0) 141 330 8734.
Tiju Joseph | alfa
Sustainable Water use in Agriculture in Eastern Europe and Central Asia
19.01.2017 | Leibniz-Institut für Agrarentwicklung in Transformationsökonomien (IAMO)
12V, 48V, high-voltage – trends in E/E automotive architecture
10.01.2017 | Haus der Technik e.V.
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences